Alkermes' Alixorexton Shows Promising Phase 2 Results for Narcolepsy Type 2 — Alkermes plc

Event summary

Alkermes' Vibrance-2 Phase 2 study of alixorexton in narcolepsy type 2 patients met dual primary endpoints, showing statistically significant improvements in wakefulness and sleepiness measures.
The study involved 93 patients and tested three doses (10 mg, 14 mg, and 18 mg) of alixorexton, with the 14 mg and 18 mg doses achieving statistical significance.
Alixorexton demonstrated clinically meaningful improvements in fatigue and cognition, with no serious adverse events reported.
Alkermes has initiated a global Phase 3 program for alixorexton, evaluating once-daily and split-dose regimens in narcolepsy type 1 and 2 patients.

The big picture

Alkermes' positive Phase 2 results for alixorexton position the company as a potential leader in the treatment of narcolepsy type 2, a condition with significant unmet medical needs. The orexin 2 receptor agonist mechanism offers a novel approach, distinguishing it from existing therapies. The initiation of Phase 3 studies marks a critical step in Alkermes' strategy to expand its neuroscience portfolio and address central disorders of hypersomnolence.

What we're watching

Regulatory Pathway: Whether the FDA and European Commission will expedite the review process for alixorexton given its Breakthrough Therapy and Orphan Drug designations.
Clinical Development: The pace at which Alkermes can enroll and complete the Phase 3 Brilliance studies, which are critical for regulatory approval.
Market Positioning: How Alkermes positions alixorexton against existing treatments for narcolepsy type 2, a market with limited therapeutic options.